KR20210005182A - 암 치료를 위한 조합 - Google Patents

암 치료를 위한 조합 Download PDF

Info

Publication number
KR20210005182A
KR20210005182A KR1020207034122A KR20207034122A KR20210005182A KR 20210005182 A KR20210005182 A KR 20210005182A KR 1020207034122 A KR1020207034122 A KR 1020207034122A KR 20207034122 A KR20207034122 A KR 20207034122A KR 20210005182 A KR20210005182 A KR 20210005182A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
azd5991
compound
acalabrutinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207034122A
Other languages
English (en)
Korean (ko)
Inventor
스캇 보이코
저스틴 시다도
리사 드류
테레사 프로이아
메리언 샌 마틴
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20210005182A publication Critical patent/KR20210005182A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207034122A 2018-04-30 2019-04-29 암 치료를 위한 조합 Ceased KR20210005182A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862664356P 2018-04-30 2018-04-30
US62/664,356 2018-04-30
PCT/IB2019/053491 WO2019211721A1 (en) 2018-04-30 2019-04-29 Combinations for treating cancer

Publications (1)

Publication Number Publication Date
KR20210005182A true KR20210005182A (ko) 2021-01-13

Family

ID=66794041

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207034122A Ceased KR20210005182A (ko) 2018-04-30 2019-04-29 암 치료를 위한 조합

Country Status (14)

Country Link
US (1) US20210030718A1 (https=)
EP (1) EP3787620A1 (https=)
JP (1) JP2021522246A (https=)
KR (1) KR20210005182A (https=)
CN (1) CN112040944A (https=)
AU (1) AU2019263026B2 (https=)
BR (1) BR112020022020A2 (https=)
CA (1) CA3097486A1 (https=)
EA (1) EA202092540A1 (https=)
MA (1) MA52499A (https=)
MX (1) MX2020011453A (https=)
SG (1) SG11202010528XA (https=)
TW (1) TW202014184A (https=)
WO (1) WO2019211721A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3158321A1 (en) * 2019-11-04 2021-05-14 Astrazeneca Ab Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
JP2023510135A (ja) * 2019-12-18 2023-03-13 ゼノ マネジメント，インコーポレイテッド 大環状化合物
JP7673255B2 (ja) 2021-06-11 2025-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
TWI910028B (zh) 2021-06-11 2025-12-21 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014001255B1 (pt) 2011-07-19 2019-07-02 Merck Sharp & Dohme B.V. Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto
CA2956550A1 (en) * 2014-08-08 2016-02-11 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof
PT3445767T (pt) * 2016-04-22 2020-05-13 Astrazeneca Ab Inibidores de mcl-1 macrocíclicos para o tratamento de cancro
CN107056786B (zh) * 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法

Also Published As

Publication number Publication date
US20210030718A1 (en) 2021-02-04
EP3787620A1 (en) 2021-03-10
CN112040944A (zh) 2020-12-04
CA3097486A1 (en) 2019-11-07
JP2021522246A (ja) 2021-08-30
AU2019263026B2 (en) 2022-06-30
EA202092540A1 (ru) 2021-03-17
WO2019211721A1 (en) 2019-11-07
MX2020011453A (es) 2020-12-07
BR112020022020A2 (pt) 2021-02-02
MA52499A (fr) 2021-04-14
SG11202010528XA (en) 2020-11-27
TW202014184A (zh) 2020-04-16
AU2019263026A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
KR20240167633A (ko) 종양 치료용 약학 조성물
JP7114478B2 (ja) 癌の治療のための配合剤
JP2023515817A (ja) ダブラフェニブ、ｅｒｋ阻害剤及びｓｈｐ２阻害剤を含む三重の医薬品の組合せ
KR20210126653A (ko) Tno155 및 리보시클립을 포함하는 약제학적 조합물
Chen et al. Clinical perspective of afatinib in non-small cell lung cancer
AU2019263026B2 (en) Combinations for treating cancer
CA2730190A1 (en) Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
JP2019511526A (ja) がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
CN113056272A (zh) 新的喹唑啉egfr抑制剂
CN111249282A (zh) 癌症疗法
WO2021210636A1 (ja) 乳がん治療剤
EP3999065B1 (en) Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers
AU2015266552A1 (en) Pharmaceutical composition comprising pyrazine carboxamide compound as active ingredient
KR20250166103A (ko) 종양 치료용 약제학적 조성물
WO2010110428A1 (ja) 掻痒の予防及び／または治療剤
CN117177752A (zh) 用于治疗mpnst的化合物和组合物
KR20240055021A (ko) Tead 저해제에 대한 투여 요법
HK40041700A (en) Combinations for treating cancer
CN102105148B (zh) 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
JP2020519581A (ja) 肥満細胞疾患の処置のための方法及び医薬組成物
AU2024229823A1 (en) Compositions and methods for making and using small molecules for the treatment of health conditions
Wang et al. Conformation-specific inhibitors of Raf kinases
US20100022553A1 (en) Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib
HK40060474A (en) Pharmaceutical combination comprising tno155 and ribociclib
CA2638270A1 (en) Therapeutic combination comprising an aurora kinase inhibitor and imatinib

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201126

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220425

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241106

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250108

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D